PHE Stock Overview
Operates as a specialty pharmaceutical company in Canada. More details
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 2/6 |
Past Performance | 1/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Cipher Pharmaceuticals Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CA$8.55 |
52 Week High | CA$13.00 |
52 Week Low | CA$3.60 |
Beta | 1.17 |
11 Month Change | -23.66% |
3 Month Change | -10.00% |
1 Year Change | 136.19% |
33 Year Change | 466.23% |
5 Year Change | 982.28% |
Change since IPO | 223.86% |
Recent News & Updates
Recent updates
Shareholder Returns
PHE | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | -17.0% | -3.1% | -0.2% |
1Y | 136.2% | -20.4% | 7.8% |
Return vs Industry: PHE exceeded the German Pharmaceuticals industry which returned -20.4% over the past year.
Return vs Market: PHE exceeded the German Market which returned 7.8% over the past year.
Price Volatility
PHE volatility | |
---|---|
PHE Average Weekly Movement | 10.0% |
Pharmaceuticals Industry Average Movement | 8.1% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.7% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: PHE's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: PHE's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2000 | n/a | Craig Mull | www.cipherpharma.com |
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome. The company’s licensed products comprise Absorica, an oral retinoid indicated for the treatment of f severe nodular and/or inflammatory acne, acne conglobate and recalcitrant acne; Lipofen, which is indicated as adjunctive therapy to diet to reduce elevated LDL-C, total-C, triglycerides, and Apo B, and to increase HDL-C, as well as to reduce triglycerides in adult patients; and Conzip, an opioid agonist indicated for the management of moderate to moderately severe chronic pain in adults.
Cipher Pharmaceuticals Inc. Fundamentals Summary
PHE fundamental statistics | |
---|---|
Market cap | €220.08m |
Earnings (TTM) | €15.04m |
Revenue (TTM) | €25.09m |
14.6x
P/E Ratio8.8x
P/S RatioIs PHE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
PHE income statement (TTM) | |
---|---|
Revenue | US$26.46m |
Cost of Revenue | US$5.09m |
Gross Profit | US$21.38m |
Other Expenses | US$5.52m |
Earnings | US$15.86m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.62 |
Gross Margin | 80.78% |
Net Profit Margin | 59.92% |
Debt/Equity Ratio | 40.5% |
How did PHE perform over the long term?
See historical performance and comparison